Quantcast

Latest Infliximab Stories

2010-10-18 10:22:00

ATLANTA, Oct. 18 /PRNewswire/ -- Findings from the PRECiSE 3 (P3) open label extension study for Cimzia® (certolizumab pegol; CZP), demonstrating the longest continuously running maintenance trial for an anti-TNF in Crohn's disease, will be exhibited at the 2010 Annual Scientific Meeting of the American College of Gastroenterology (ACG), taking place in San Antonio from October 15 - 20. Additionally, long-term efficacy data from the PRECiSE 4 (P4) clinical trial also will...

2010-10-15 09:00:00

ATLANTA, Oct. 15 /PRNewswire/ -- Studies and analyses of the Crohn's disease (CD) treatment Cimzia® (certolizumab pegol) will be exhibited at the 2010 Annual Scientific Meeting of the American College of Gastroenterology, taking place in San Antonio from October 15 - 20. "Cimzia data at this year's ACG meeting continue to demonstrate real-life significance to those with moderate to severe Crohn's disease who have tried other therapies with no response or have never...

2010-10-14 08:00:00

BURLINGTON, Mass., Oct. 14 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, between 2010 and 2013, surveyed European rheumatologists expect well-established TNF-alpha inhibitors to lose considerable patient share to newer agents in this drug class, most notably Centocor Ortho Biotech/Merck/Mitsubishi Tanabe/Janssen's Simponi and UCB/Otsuka's Cimzia. The increased use of newer agents such as...

2010-10-05 07:00:00

BURLINGTON, Mass., Oct. 5 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that, in the ulcerative colitis drug market, modest growth of $800 million though 2019 will be driven by the uptake of Abbott/Eisai's Humira, Centocor Ortho Biotech/Merck/Mitsubishi Tanabe Pharma/Janssen's Simponi and Millennium's vedolizumab in the United States, France, Germany, Italy, Spain, United Kingdom and Japan. The...

2010-09-29 08:30:00

BURLINGTON, Mass., Sept. 29 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that the Crohn's disease drug market will experience moderate growth over the next decade, increasing from $3.2 billion in 2009 to $4.2 billion in 2019 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan. This modest growth rate masks dramatic changes as market growth from newer and emerging biologic...

2010-09-22 07:00:00

BURLINGTON, Mass., Sept. 22 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that while Amgen/Stiefel/Pfizer's Enbrel is the most popular biologic across all lines of therapy for psoriasis treatment in newly diagnosed patients, Abbott's Humira is gaining increasing use as a first-line biologic at Enbrel's expense. According to the new report entitled Treatment Algorithms in Psoriasis, dermatologists'...

2010-09-16 12:12:00

SAN DIEGO, Sept. 16 /PRNewswire/ -- Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, and Tarrot Laboratories, a business unit of Cedars-Sinai Medical Center, today announced the execution of an exclusive research collaboration and license agreement. The collaboration will focus on identifying genetic or serologic markers associated with clinical responses to anti-TNF therapies such as Cimzia®, Humira® and...

2010-08-31 07:00:00

EXTON, Pa., Aug. 31 /PRNewswire/ -- BioTrends has released the third and final wave of LaunchTrends®: ACTEMRA. Actemra (tocilizumab), marketed by Roche-Genentech, is the first humanized IL-6 receptor inhibitor agent approved for moderate-to-severe rheumatoid arthritis (RA) patients with an inadequate response to one or more TNF-alpha inhibitors. This report is derived from on-line survey responses from 75 rheumatologists and qualitative interviews with a subset of the...

2010-08-09 07:00:00

CHICAGO, Aug. 9 /PRNewswire/ -- New study findings showed that a majority of patients with moderate to severe plaque psoriasis who had a previous response to STELARA® (ustekinumab) sustained a clinical response for up to three years with continued treatment regardless of their body weight. Investigators also presented findings from an integrated safety analysis that included data from one Phase 2 and three Phase 3 trials in which treatment with STELARA demonstrated a...

2010-08-05 16:18:43

Biological agents may play an important role in maintaining remission in Crohn's disease, according to two new studies in Clinical Gastroenterology and Hepatology, the official journal of the American Gastroenterological Association (AGA) Institute. "Post-surgical recurrence of Crohn's disease occurs very frequently. Unfortunately, none of the traditional drugs used to treat the naturally occurring disease has really shown a clear-cut benefit in this situation," said Dario R. Sorrentino, MD,...


Word of the Day
grass-comber
  • A landsman who is making his first voyage at sea; a novice who enters naval service from rural life.
According to the OED, a grass-comber is also 'a sailor's term for one who has been a farm-labourer.'